Six peptides received narrow advisory support for potential 503A Bulks List inclusion, an atypical outcome given FDA staff recommendations against all seven under review. Legal compounding remains ...
EBV seroconversion confers markedly increased MS risk in large longitudinal military cohorts, supporting EBV as necessary but ...
High-frequency, low-dose rituximab achieved ~85% peripheral CLL clearance within 1 hour and ~34% nodal reduction in 1 week, with macrophage phagocytosis and complement as dominant mechanisms.
Right-sided performance improved most, with adenoma detection rising from 18.0% to 31.8%, addressing a common vulnerability of standard colonoscopy quality and missed proximal lesions.
The study, “Geographical Access to Preferred Pharmacies in Medicare Part D,” published in the July 2026 issue of The American Journal of Managed Care ® (AJMC ®), analyzed pr ...
This segment explores emerging challenges in treatment sequencing for hormone receptor–positive, HER2-negative metastatic breast cancer as oral selective estrogen receptor degraders move into earlier ...
Vitiligo's clinical course splits into segmental and non-segmental presentations, each carrying a distinct prognosis. Dr. Rosmarin explains how disease activity, not just extent, determines whether a ...
CTGTAC concluded the evidentiary package did not substantiate clinical benefit for DMD cardiomyopathy, with multiple members characterizing the efficacy findings as statistically and clinically ...
A federal judge heard arguments over whether CMS unlawfully narrowed the Medicaid work requirement exemption for medically frail beneficiaries. Richard G. Stearns of the U.S. District Court for the ...
Congressional Republicans support enforcing diversity action plan requirements while distancing them from DEI rhetoric, amid uncertainty created by removal and altered reinstatement of FDA draft ...
Young adults with sarcoma face challenges that extend well beyond treatment, and closing gaps in research funding and specialty care could improve outcomes for this population and beyond, according to ...
Anosheh Afghahi, MD, discusses biomarker testing, trial matching technology, and community-academic partnerships to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results